HeartBeam Q1 net loss narrows as commercialization advances

Heartbeam

13/05/2026 21:17

Overview

U.S. cardiac technology firm's Q1 net loss narrowed yr/yr as commercialization initiatives advanced

Cash and cash equivalents totaled $2.0 mln this quarter, a decrease compared to last year

HeartBeam signed first commercial partners and launched pilot studies for heart attack detection

Outlook

HeartBeam aims to expand commercial footprint and deepen adoption at flagship accounts in 2026

Company to advance heart attack detection, ECG patch, and AI initiatives throughout 2026

Result Drivers

COMMERCIAL PARTNERSHIPS - Co said first commercial deals with ClearCardio and Atelier Health established flagship sites in targeted U.S. regions

TECHNOLOGY PILOT STUDIES - Co launched pilot studies for heart attack detection and on-demand 12-lead ECG patch

AI COLLABORATION - Strategic partnership with Mount Sinai to develop next-generation AI-ECG algorithms

Company press release: ID:nBw45ycyLa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.12


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Heartbeam Inc is $4.75, about 421.1% above its May 12 closing price of $0.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)